Regional evidence of modulation of cardiac adiponectin level in dilated cardiomyopathy: Pilot study in a porcine animal model

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Caselli, Chiara ^a   Lionetti, Vincenzo ^b   Cabiati, Manuela ^a   Prescimone, Tommaso ^a   Aquaro, Giovanni D ^c   Ottaviano, Virginia ^d   Bernini, Fabio ^c   Mattii, Letizia ^d   Del Ry, Silvia ^a   Giannessi, Daniela ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Adiponectin; Adiponectin receptors; AMPK; Animal models; Heart failure

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HEART; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; MALE; NONHUMAN; UPREGULATION;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HEART FAILURE; MALE; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE II; PILOT PROJECTS; PPAR ALPHA; PPAR GAMMA; RECEPTORS, ADIPONECTIN; RNA, MESSENGER; STROKE VOLUME; SWINE; SWINE, MINIATURE; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84869135012     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-143     Document Type: Article

References (51)

1. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chem Acta 2007, 380:24-30.
2. Ding G, Qin Q, He N, Francis-David SC, Hou J, Liu J, Ricks E, Yang Q. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J Mol Cell Cardiol 2007, 43:73-84. 10.1016/j.yjmcc.2007.04.014, 1950729, 17532004.
3. Cao Y, Tao L, Yuan Y, Jiao X, Lau WB, Wang Y, Christopher T, Lopez B, Chan L, Goldstein B, Ma XL. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009, 46:413-419. 10.1016/j.yjmcc.2008.10.014, 2671019, 19027750.
4. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Christopher T, Lopez B, Chan L, Goldstein B, Ma XL. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769. 10.1038/nature01705, 12802337.
5. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010, 120:4342-4352. 10.1172/JCI43464, 2993592, 21041950.
6. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res 2011, 90:202-209. 10.1093/cvr/cvr038, 3078800, 21289012.
7. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451. 10.1210/er.2005-0005, 15897298.
8. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Cir Res 2007, 101:27-39.
9. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanism. Nat Med 2005, 11:1096-1103. 10.1038/nm1295, 2828682, 16155579.
10. Giannessi D, Maltinti M, Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007, 56:459-467. 10.1016/j.phrs.2007.09.014, 18029194.
11. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009, 6:27-35. 10.1038/ncpcardio1398, 2658652, 19029992.
12. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y, Osaka CAD Study Group Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89. 10.1161/01.ATV.0000048856.22331.50, 12524229, Osaka CAD Study Group.
13. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004, 90:528-533. 10.1136/hrt.2003.011114, 1768199, 15084551.
14. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747-753. 10.1161/01.CIR.0000155251.03724.A5, 15699257.
15. von Eynatten M, Humpert PM, Bluemm A, Lepper PM, Hamann A, Allolio B, Nawroth PP, Bierhaus A, Dugi KA. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008, 199:123-128. 10.1016/j.atherosclerosis.2007.10.002, 18021784.
16. Kollias A, Tsiotra PC, Ikonomidis I, Maratou E, Mitrou P, Kyriazi E, Boutati E, Lekakis J, Economopoulos T, Kremastinos DT, Dimitriadis G, Raptis SA. Adiponectin levels and expression of adiponectin receptors in isolated monocytes from overweight patients with coronary artery disease. Cardiovasc Diabetol 2011, 1:10-14.
17. Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, de Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 2011, 19:10-67.
18. Giannessi D, Caselli C, Del Ry S, Maltinti M, Pardini S, Turchi S, Cabiati M, Sampietro T, Abraham N, L'abbate A, Neglia D. Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure. Metabolism 2011, 60:227-233. 10.1016/j.metabol.2009.12.030, 20199784.
19. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, Horie M. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007, 28:1723-1730. 10.1093/eurheartj/ehm154, 17507366.
20. Kistorp C, Faber J, Galatius S, Gustafsson F, Frysryk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762. 10.1161/CIRCULATIONAHA.104.530972, 16157772.
21. Kintscher U. Does adiponectin resistance exist in chronic heart failure?. Eur Heart J 2007, 28:1676-1677. 10.1093/eurheartj/ehm233, 17591684.
22. Lionetti V, Guiducci L, Simioniuc A, Aquaro GD, Simi C, De Marchi D, Burchielli S, Pratali L, Piacenti M, Lombardi M, Salvadori P, Pingitore A, Neglia D, Recchia FA. Mismatch between uniform increase in cardiac glucose uptake and regional contractile dysfunction in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2007, 293:2747-2756.
23. Lionetti V, Aquaro GD, Simioniuc A, Di Cristofano C, Forini F, Cecchetti F, Campan M, De Marchi D, Bernini F, Grana M, Nannipieri M, Mancini M, Lombardi M, Recchia FA, Pingitore A. Severe mechanical dyssynchrony causes regional hibernation-like changes in pigs with nonischemic heart failure. J Card Fail 2009, 15:920-928. 10.1016/j.cardfail.2009.06.436, 19944370.
24. Prinzen FW, Hunter WC, Wyman BT, McVeigh ER. Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. J Am Coll Cardiol 1999, 33:1735-1742. 10.1016/S0735-1097(99)00068-6, 2041911, 10334450.
25. Del Ry S, Cabiati M, Lionetti V, Simioniuc A, Caselli C, Prescimone T, Emdin M, Giannessi D. Asymmetrical myocardial expression of natriuretic peptides in pacing-induced heart failure. Peptides 2009, 30:1710-1713. 10.1016/j.peptides.2009.06.013, 19540894.
26. Martino A, Cabiati M, Campan M, Prescimone T, Minocci D, Caselli C, Rossi AM, Giannessi D, Del Ry S. Selection of reference genes for normalization of real time PCR data in minipig heart failure model and evaluation of TNF alpha mRNA expression. J Biotechnol 2011, 153:92-99. 10.1016/j.jbiotec.2011.04.002, 21510983.
27. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:RESEARCH0034. 126239, 12184808.
28. Takano H, Obata J, Kodama Y, Kitta Y, Nakamura T, Mende A, Kawabata K, Saito Y, Fujioka D, Kobayashi T, Yano T, Sano K, Kugiyama K. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol 2009, 20:221-226.
29. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009, 53:2070-2077. 10.1016/j.jacc.2009.02.038, 19477358.
30. Tanaka K, Tsutamoto T, Sakai H, Nishivama K, Fujii M, Yamamoto T, Horie M. Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur J Heart Fail 2008, 10:360-366. 10.1016/j.ejheart.2008.02.005, 18353720.
31. Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001, 38:436-442. 10.1016/S0735-1097(01)01383-3, 11499735.
32. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007, 28:829-835. 10.1093/eurheartj/ehm033, 17403719.
33. Lau CH, Muniandy S. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovasc Diabetol 2011, 21(10(1)):8.
34. Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, New J, Gibson JM, Neyses L. Impaired glucose tolerance and insulin resistance in heart failure: under-recognized and under-treated?. J Card Fail 2010, 16:761-768. 10.1016/j.cardfail.2010.05.027, 20797600.
35. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R, Conraads VM. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010, 3:185-194. 10.1161/CIRCHEARTFAILURE.109.885525, 20103776.
36. Skurk C, Wittchen F, Suckau L, Witt H, Noutsias M, Fechner H, Schultheiss HP, Poller W. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 2008, 29:1168-1180. 10.1093/eurheartj/ehn136, 18390538.
37. Wittchen F, Suckau L, Witt H, Skurk C, Lassner D, Fechner H, Sipo I, Ungethüm U, Ruiz P, Pauschinger M, Tschope C, Rauch U, Kühl U, Schultheiss HP, Poller W. Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets. J Mol Med 2007, 85:257-271. 10.1007/s00109-006-0122-9, 1820750, 17106732.
38. Liao Y, Xuan W, Zhao J, Bin J, Zhao H, Asakura M, Funahashi T, Takashima S, Kitakaze M. Antihypertrophic effects of adiponectin on cardiomyocytes are associated with the inhibition of heparin-binding epidermal growth factor signaling. Bioch Biophy Res Com 2010, 393:519-525.
39. Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS, Sam F, Ouchi N, Walsh K. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 2007, 42:1065-1074. 10.1016/j.yjmcc.2007.03.808, 1987393, 17499764.
40. Kondo K, Shibata R, Unno K, Shimano M, Ishii M, Kito T, Shintani S, Walsh K, Ouchi N, Murohara T. Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Interv 2010, 3:166-173. 10.1161/CIRCINTERVENTIONS.109.872044, 20332381.
41. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, Igura T, Inui Y, Kihara S, Nakamura T, Yamashita S, Miyagawa J, Funahashi T, Matsuzawa Y. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000, 32:47-50. 10.1055/s-2007-978586, 10741683.
42. Li R, Wang WQ, Zhang H, Yang X, Fan Q, Christopher TA, Lopez BL, Tao L, Goldstein BJ, Gao F, Ma XL. Reduced vascular responsiveness to adiponectin in hyperlipidemic rats-mechanisms and significance. J Mol Cell Cardiol 2010, 49:508-515. 10.1016/j.yjmcc.2010.03.002, 2904862, 20303976.
43. Liu S, Yin T, Wei X, Yi W, Qu Y, Liu Y, Wang R, Lian K, Xia C, Pei H, Sun L, Ma Y, Lau WB, Gao E, Koch WJ, Wang H, Tao L. Downregulation of adiponectin induced by tumor necrosis factor α is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med 2011, 39:1935-1943. 10.1097/CCM.0b013e31821b85db, 21499085.
44. Sen B, Xie Z, Case N, Ma M, Rubin C, Rubin J. Mechanical strain inhibits adipogenesis in mesenchymal stem cells by stimulating a durable beta-catenin signal. Endocrinology 2008, 149:6065-6075. 10.1210/en.2008-0687, 2613068, 18687779.
45. Wang Y, Gao E, Tao L, Lau WB, Yuan Y, Goldstein BJ, Lopez BL, Christopher TA, Tian R, Koch W, Ma XL. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009, 119:835-844. 10.1161/CIRCULATIONAHA.108.815043, 2658653, 19188503.
46. Ikeda Y, Ohashi K, Shibata R, Pimentel DR, Kihara S, Ouchi N, Walsh K. Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett 2008, 582:1147-1150. 10.1016/j.febslet.2008.03.002, 2423200, 18339320.
47. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011, 17:55-63. 10.1038/nm.2277, 3134999, 21186369.
48. Kadowaki T, Yamauchi T. Adiponectin receptor signaling: a new layer to the current model. Cell Metab 2011, 13:123-124. 10.1016/j.cmet.2011.01.012, 21284979.
49. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 2011, 90:224-233. 10.1093/cvr/cvr034, 21285292.
50. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 16:328-341.
51. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009, 2:262-271. 10.1161/CIRCHEARTFAILURE.108.814459, 2762217, 19808348.